As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
JMCP Outsert - CLL (Health Plan)
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin. View a patient case study and treatment plan that was discussed through the AMCP Marketing Insights Program.
For more disease state research, view the Market Insights Program.
Related
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Metabolic diseases drive rising costs and disparities, yet evidence‑based care remains inconsistent. AMCP is advancing guidance, education, and collaboration to support aligned coverage, equitable access, and improved outcomes.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
